ROCKWELL MEDICAL, INC. (RMTI) SEC Filings & Earnings Calls
EquiReason read 12 ROCKWELL MEDICAL, INC. SEC filings in the last 12 months. Latest: 8-K on 2026-08-13 — Rockwell Medical furnished an updated corporate presentation under Item 7.01. No material financial or operational event disclosed..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 28.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
13 Aug 202610-QRockwell Medical reported Q2 2026 net sales of $17.8M (+11% YoY) and improved gross margin to 18%, with operating loss narrowing.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q2-2026 | $18M | +11% y/y |
| Gross Profit · Q2-2026 | $3M | +30% y/y |
| Operating Loss · Q2-2026 | $-1M | -21% y/y |
| Net Sales · H1-2026 | $35M | 0% y/y |
| Gross Profit · H1-2026 | $6M | +11% y/y |
| Operating Loss · H1-2026 | $-3M | -6% y/y |
| Cash and Equivalents · 2026-06-30 | $25M | |
| Net Working Capital · 2026-06-30 | $25M | |
| Operating Cash Flow · H1-2026 | $2M |
Risks flagged
Customer concentration risk
“DaVita represented 7% and 20% of net sales for the six months ended June 30, 2026 and 2025, respectively.” · word for word
Going concern risk
“If we are unsuccessful in executing our business plan and we are unable to raise the required capital, we may be forced to curtail all of our activities and, ultimately, cease operations.” · word for word
Debt covenant risk
“The Company is subject to certain covenants and cure provisions under its Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP.” · word for word
13 Aug 20268-K · 2.02Q2 2026 net sales up 11% YoY, gross profit up 30%, gross margin expanded to 18%, cash flow from operations positive; reiterated 2026 guidance.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q2-2026 | $18M | +11% y/y |
| Gross Profit · Q2-2026 | $3M | +30% y/y |
| Gross Margin · Q2-2026 | 18.0% | |
| Net Loss · Q2-2026 | $-1M | |
| Adjusted EBITDA · Q2-2026 | $-200000.00 | |
| Cash and Cash Equivalents and Investments Available-for-Sale · Q2-2026 | $25M | |
| Cash Flow from Operations · Q2-2026 | $2M |
Guidance
Net Sales $70M-$75M, Gross Margin 18%-22%, Adjusted EBITDA $1M-$2M, Operating Cash Flow Positive
Reiterated 2026 annual guidance; on track to achieve full-year guidance with emphasis on top line growth, improving gross margins and positive cash flow.
20 Jul 20268-K · 8.01Rockwell Medical received Nasdaq notification that it has regained compliance with the minimum $1.00 bid price requirement, closing the compliance matter.open
Risks flagged
Previously at risk of delisting due to low bid price; now resolved.
“Company has regained compliance with minimum $1.00 per share bid price requirement.”
7 May 20268-K · 2.02Rockwell Medical reports Q1 2026 net sales $17.3M (down 8% YoY), gross margin 17% (up from 16%), net loss $1.6M, and updates 2026 guidance: net sales $70-75M, gross margin 18-22%, Adj. EBITDA $1-2M, positive operating cash flow.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q1-2026 | $17M | -8% y/y |
| Gross Profit · Q1-2026 | $3M | -3% y/y |
| Gross Margin · Q1-2026 | 17.0% | |
| Net Loss · Q1-2026 | $-2M | +7% y/y |
| Adjusted EBITDA · Q1-2026 | $-300000.00 | -25% y/y |
| Cash and Cash Equivalents and Investments Available-for-Sale · Q1-2026 | $24M | -4% y/y |
Guidance
FY2026 net sales $70.0M to $75.0M; gross margin 18% to 22%; Adjusted EBITDA $1.0M to $2.0M; operating cash flow positive
2026 guidance updated with focus on profitability: net sales $70-75M, gross margin 18-22%, Adj. EBITDA $1-2M, positive operating cash flow.
Risks flagged
Customer concentration risk: net sales decline driven by reduced purchase volume from one customer.
“The decrease in net sales was driven by a reduction in purchase volume by one of the Company's customers.” · word for word
7 May 202610-QRMTI reported Q1 2026 net sales of $17.3M, down 8% YoY, with improved gross margin and reduced cash burn.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $17M | -8% y/y |
| Operating Cash Flow · Q1-2026 | $-200000.00 |
Risks flagged
Customer concentration risk
“DaVita represented 7% and 27% of net sales for the three months ended March 31, 2026 and 2025, respectively.” · word for word
Going concern risk
“If we are unsuccessful in executing our business plan and we are unable to raise the required capital, we may be forced to curtail all of our activities and, ultimately, cease operations.” · word for word
30 Apr 2026DEF 14ADefinitive proxy statement for 2026 annual meeting, including proposals to elect directors, advisory vote on executive compensation, ratify auditors, and approve a reverse stock split to maintain Nasdaq listing.open
Figures in the filing · each found in the filing text
| Net Loss · FY2025 | $-5M | |
| Total Shareholder Return (TSR) · FY2025 | $82.12 | |
| Stock Price · 2026-04-16 | $0.92 | |
| Shares Outstanding · 2026-04-16 | 39,405,302 |
Risks flagged
Nasdaq Delisting Risk
“The closing price of our common stock on April 16, 2026 was $0.92.” · word for word
Reverse Stock Split Execution Risk
“There can be no assurance that the total market capitalization of our common stock after the implementation of the Reverse Stock Split will be equal to or greater than the total market capitalization before the Reverse Stock Split.” · word for word
Stock Price Volatility
“The trading price of our common stock may change due to a variety of other factors, including our ability to successfully accomplish our business goals, market conditions and the market perception of our business.” · word for word
26 Mar 202610-KRockwell Medical reported a 31.8% revenue decline and an operating loss for FY2025, driven by DaVita's transition away from the company.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · FY2025 | $69M | -32% y/y |
| Operating (Loss) Income · FY2025 | $-5M | |
| Net Cash Used in Operating Activities · FY2025 | $-700000.00 |
Risks flagged
Customer Concentration
“DaVita represented 16% and 45% of net sales for the years ended December 31, 2025 and 2024, respectively.” · word for word
Going Concern Uncertainty
“management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.” · word for word
Liquidity Risk
“Net cash used in operating activities was $0.7 million for the year ended December 31, 2025.” · word for word
26 Mar 20268-K · 2.02Rockwell Medical reported Q4/FY2025 results: net sales $18.3M/$69.3M, gross margin improved to 21% (Q4) from 15% YoY, achieved positive Adj EBITDA for second consecutive year, cash increased to $25.0M. Revenue declined due to customer volumearningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q4-2025 | $18M | -26% y/y |
| Net Sales · FY2025 | $69M | -32% y/y |
| Gross Profit · Q4-2025 | $4M | +8% y/y |
| Gross Profit · FY2025 | $12M | -33% y/y |
| Gross Margin · Q4-2025 | 21.0% | |
| Gross Margin · FY2025 | 17.0% | |
| Net Income (Loss) · Q4-2025 | $-600000.00 | -25% y/y |
| Net Income (Loss) · FY2025 | $-5M | +960% y/y |
| Adjusted EBITDA · Q4-2025 | $1M | -23% y/y |
| Adjusted EBITDA · FY2025 | $300000.00 | -94% y/y |
Risks flagged
Customer concentration risk: revenue decline driven by reduced purchase volume from one customer.
“The decrease in net sales was driven by a reduction in purchase volume by one of the Company's customers.” · word for word
Net loss widened significantly in FY2025 ($5.3M) vs FY2024 ($0.5M), partly due to non-cash charges and severance costs.
“Net loss for the twelve months ended December 31, 2025 was $5.3 million, compared to a net loss of $0.5 million for the same period in 2024.” · word for word
20 Jan 20268-K · 2.02Preliminary Q4 2025 results: net sales ~$18.6M (FY $69.5M), gross margin 22% (up from 14% in Q3), cash flow from ops ~$2.3M, cash ~$25M. Positive trends in revenue, margin, cash flow.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q4-2025 | $19M | |
| Net sales · FY2025 | $70M | |
| Gross margin · Q4-2025 | 22.0% | |
| Cash flow from operations · Q4-2025 | $2M | |
| Cash and cash equivalents and investments available-for-sale · Q4-2025 | $25M |
Risks flagged
Preliminary results subject to adjustment
“Preliminary unaudited financial results are subject to adjustments based on completion of year-end financial close process.”
12 Nov 20258-K · 2.02Rockwell Medical Q3 2025 net sales $15.9M (-44% YoY) due to largest customer loss. Net loss $1.8M vs income $1.7M prior year. Reiterates FY2025 guidance: net sales $65-70M, gross margin 16-18%, Adj. EBITDA ($0.5M). Cash increased to $23.7M.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q3-2025 | $16M | -44% y/y |
| Gross Margin · Q3-2025 | 14.0% | |
| Adjusted EBITDA · Q3-2025 | $50000.00 | -98% y/y |
| Cash, Cash Equivalents and Investments Available-for-Sale · Q3-2025 | $24M | +29% y/y |
| Basic Net Income (Loss) per Share · Q3-2025 | $-0.05 | -200% y/y |
Guidance
FY2025 net sales $65.0M to $70.0M; gross margin 16% to 18%; Adjusted EBITDA ($0.5M)
Company reiterates 2025 guidance despite significant revenue decline, indicating expected stabilization.
Risks flagged
Customer concentration risk: loss of largest customer drove 44% revenue decline.
“The decrease in net sales was driven by the Company's largest customer transitioning to another supplier.” · word for word
Profitability reversal: net loss of $1.8M vs net income of $1.7M prior year.
“Net loss for Q3 2025 was $1.8 million compared to net income of $1.7 million for same period in 2024.”
12 Nov 202510-QQ3 2025 revenue fell 44% YoY due to DaVita transitioning to a new supplier; gross margin compressed; operating loss.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q3-2025 | $16M | -44% y/y |
| Gross Profit · Q3-2025 | $2M | -64% y/y |
| Operating (Loss) Income · Q3-2025 | $-2M | |
| Net Sales (9 months) · 9M-2025 | $51M | -34% y/y |
| Gross Profit (9 months) · 9M-2025 | $8M | -44% y/y |
| Operating (Loss) Income (9 months) · 9M-2025 | $-4M | |
| Cash, Cash Equivalents and Investments Available-for-Sale · 2025-09-30 | $24M |
Risks flagged
Customer concentration risk
“DaVita represented 12% and 52% of net sales for the three months ended September 30, 2025 and 2024, respectively.” · word for word
Going concern risk
“If we are unsuccessful in executing our business plan and we are unable to raise the required capital, we may be forced to curtail all of our activities and, ultimately, cease operations.” · word for word
Debt covenant risk
“The Company is subject to certain covenants and cure provisions under its Loan and Security Agreement... As of September 30, 2025, the Company was in compliance with all covenants.” · word for word
ROCKWELL MEDICAL, INC. — questions
- What did ROCKWELL MEDICAL, INC. file recently?
- 12 SEC filings in the last 12 months. Latest: 8-K on 2026-08-13 — Rockwell Medical furnished an updated corporate presentation under Item 7.01. No material financial or operational event disclosed.
Every figure on this page comes from ROCKWELL MEDICAL, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.